Please use this identifier to cite or link to this item:
|Title:||Moderate alcohol use in fatty liver disease; don't throw the cabernet out with the bathwater.||Austin Authors:||Gow, Paul J ;Testro, Adam G ;Hey, Penelope ;Sinclair, Marie||Affiliation:||Victorian Liver Transplant Unit, Austin Health, Heidelberg, Victoria, Australia
The University of Melbourne, Victoria, Australia
|Issue Date:||29-Nov-2019||metadata.dc.date:||2019-11-29||Publication information:||Hepatology (Baltimore, Md.) 2019; online first: 29 November||Abstract:||We congratulate Dr Aberg and colleagues for a significant contribution to the literature on the important topic of moderate alcohol use in fatty liver disease (NAFLD) (1). Approximately 30% of the population of the Western world has obesity and/or other complications of insulin resistance and the metabolic syndrome. Due to the magnitude of this problem worldwide, palatable lifestyle therapies that are affordable, available and acceptable are necessary to curtail preventable early deaths. Moderate alcohol has the potential to fill this space, although knowledge remains limited.||URI:||http://ahro.austin.org.au/austinjspui/handle/1/22109||DOI:||10.1002/hep.31049||PubMed URL:||31782819||Type:||Journal Article||Subjects:||NAFLD
|Appears in Collections:||Journal articles|
Show full item record
checked on Dec 9, 2022
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.